TrialAmerican journal of clinical dermatology2026

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).

Christopher G Bunick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.